Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

Hims & Hers Health shares jumped 11.07% to $26.98 after the FDA said it may review compounded peptide therapies, potentially opening a new product pathway for the telehealth company. Volume surged to 74.6 million shares, about 111% above its three-month average of 35.3 million, indicating strong investor interest. Bank of America reiterated a neutral rating but raised its price target to $25 from $21, citing optionality from the company’s manufacturing assets.

Analysis

The move in HIMS is less about one peptide headline and more about a rerating of regulatory optionality. If the FDA ultimately narrows or removes restrictions, the company’s earlier manufacturing investment becomes a real operating leverage story: owned supply can shift from a marketing asset to a margin weapon, and first-mover advantage matters because consumer-health demand is sticky once a regimen is established. The key second-order effect is that a cleaner regulatory pathway could compress the advantage of smaller gray-market compounding shops, while forcing larger incumbents to either partner or build capacity, which should favor the best-distributed brand.

The market is probably discounting a months-long process as if it were a binary near-term approval, which creates event risk. The bigger risk is not denial so much as delay: if the FDA opens review but punts on final action, speculative flows can unwind quickly because today’s move was driven by positioning rather than current earnings power. That makes the stock vulnerable to a 15-25% air pocket if follow-through data or official guidance fails to arrive within the next 4-8 weeks.

From a competitive lens, TDOC and AMWL are not direct peptide beneficiaries, but the headline can still matter for sentiment across online healthcare. HIMS’ outperformance may pull incremental attention away from the weaker balance-sheet names, while AMWL remains the cleaner short if the market starts treating the group as a relative-winner/relative-loser setup. Bank of America’s higher target is important mainly because it validates the manufacturing option value, but it still leaves plenty of room for disappointment if the pathway is narrower than bulls expect.

Key Decisions for Investors

• Go long HIMS only on pullbacks toward the low-$20s or via a 30-45 day call spread; the setup is attractive if you believe FDA optionality survives, but current pricing already reflects a meaningful probability of success.
• Buy HIMS Jan-2026 call spreads for defined risk; the thesis is a 6-12 month rerating if peptide access becomes explicit, with upside tied to margin expansion rather than just top-line growth.
• Pair trade: long HIMS / short AMWL for 1-3 months; HIMS has the regulatory catalyst and manufacturing leverage, while AMWL is more exposed to sentiment spillover without a comparable self-help driver.
• For event-driven traders, hedge HIMS longs with short-dated puts into any FDA milestone; implied volatility should remain elevated, and the risk/reward favors owning convexity while capping downside on a headline reversal.
• Take profit on incremental HIMS strength above the prior spike zone if there is no concrete FDA follow-up within 2-4 weeks; the move looks flow-driven enough to fade if the catalyst becomes non-committal.